INTRODUCTION
Olfactory dysfunction in general and impaired olfactory identification (OI) in particular have been reported in Alzheimer's disease (AD) and are found to occur at early stages of the disease (Mesholam et al., 1998) . It has been indicated that involvement of the olfactory bulb and tract is one of the earliest events in the degenerative process on the central nervous system in AD (Christen-Zaech et al., 2003) and also that tau pathology in the olfactory bulb increases with severity of AD (Attems et al., 2005) . All published reports of OI in AD have demonstrated deficits related to healthy controls (Rahayel et al., 2012) and its utility as a biomarker to predict cognitive decline and AD in elderly cognitively normal people and those with mild cognitive impairment (MCI) (Devanand et al., 2015; Lafaille-Magnan et al., 2017; Woodward et al., 2017) . A recent meta-analysis has shown that OI amongst the olfactory deficits to be most impaired in MCI (average age 72.83 years) (Roalf et al., 2017) .
Strong correlations of OI with cognition in AD patients have been identified, showing the potential of OI testing as a disease and progression marker (Suzuki et al., 2004; Velayudhan et al., 2013) .
Early-onset dementia is defined as dementia starting before the age of 65, a cut off based on a social partition of retirement age rather than biological one (Rossor et al., 2010) .
Although it is well established that patients with late onset AD and elderly MCI perform significantly more poorly than matched controls in their olfactory identification function, there is little information on OI in people with early onset AD (EOAD) and early onset MCI (eoMCI) (<65 years) compared to control subjects. We aimed to establish differences in OI 5 function between people with EOAD, eoMCI and age-matched healthy controls (HC), and to study the association of OI function with cognition and non-cognitive symptoms. Disorders Association (NINCDS-ADRDA) criteria (McKhann et al., 1984) . The exclusion criteria were dementia other than AD; history of psychiatric disorder, including substance abuse.
METHODS

Subjects:
Mild
eoMCI Participants (MMSE score 24-30) (n=17) aged < 65 years, were recruited following clinical diagnosis as per ICD 10 code (F06.7) from YODAS within MHSOP, Leicestershire Partnership NHS Trust, UK. Diagnosis of MCI was made following a semi structured interview with an experienced psychiatrist, comprehensive cognitive testing and dementia screen, including blood testing and neuroimaging. Exclusion Criteria included history of any type of dementia or psychiatric disorder.
Healthy Controls (HC) (n=21) were recruited from a group of interested healthy volunteers (9 domestic partners, 4 first degree relatives and 8 unrelated volunteers) and were within +/-5 years of age of the EOAD and eoMCI participants. They had no complaints of memory 6 or functional decline. They did not have diagnosis of dementia or MCI. The MMSE score range was 27-30.
The exclusion criteria were those with diagnosis of dementia, significant neurological or psychiatric illness, significant unstable systematic illness or organ failure.
All participants had either no history at all of cigarette smoking or had stopped smoking for 20 years or more. They also did not have acute or chronic medical conditions that may affect cerebral functioning or other conditions known to affect olfactory functioning such as common cold, polyps.
Informed consent or assent, as appropriate was taken from all the participants. The study had approval from East Midlands region NHS Research Ethics Committee and the recruitment was completed during the period 2013-2015.
Assessments
Assessment included cognitive testing with MMSE (Folstein et al., 1975) for all 3 groups and CAMCOG part of Cambridge Mental Disorders of the Elderly Examination (CAMDEX) (Roth et al., 1986) in addition for EOAD and eoMCI group. For non-cognitive symptoms Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) and Bristol Activities of Daily Living Scale (BADL) (Bucks et al., 1996) were used. University of Pennsylvania smell identification test (UPSIT) was used, a standardised test for OI (higher scores reflecting better performance) and for which prior evaluation has indicated high reliability (Doty et al., 1984) .
Data analysis was done using SPSS 22.0. Comparisons were made on demographic information, clinical characteristics, and cognitive and behavioural test results using the Chi-7 square test for categorical outcomes and student t-tests and Spearman rank correlations for continuous variables as appropriate. Logistic regression analysis was carried out with diagnosis (EOAD vs eoMCI and eoMCI vs HC) as the dependent variables and age, sex, education UPSIT, MMSE, CAMCOG and BADL as independent variables.
RESULTS
None of the patient participants had speech or language difficulties. All participants were White Europeans except for 3 EOAD patients (Asian), 5 eoMCI patients (1 Afro-Caribbean and 4 Asian) and 1 HC (Asian).
The socio-demographic and clinical comparisons between the subjects with EOAD, eoMCI and the HC are as described in Table 1 . The EOAD group scored lower on the MMSE (t(34) =-2.980, p=0.005) and UPSIT measures (t(34) =-4.153, p<0.001) than eoMCI and similarly scored lower on MMSE (t(38) =-5.389, p<0.001) and UPSIT (t(38) =-3.448, p=0.001) compared to HC. The eoMCI participants scored lower than HC group on the MMSE (t(36)=-4.241, p<0.001); however, there was no difference between the two groups on UPSIT scores (t(36) =0.188, p=0.852). Total UPSIT scores correlated with MMSE (r= 0.462, p<0.001) and total CAMCOG (r= 0.509, p<0.001) for the EOAD and eoMCI groups. Within the EOAD group the total UPSIT scores correlated with MMSE (r=0.477 and p=0.039) and with CAMCOG subitems i.e., executive functions (r= 0.508, p= 0.026), attention (r= 0.494, p= 0.031) and praxis (r= 0.455, p= 0.050).
Logistic regression analysis using both adjusted and unadjusted models showed that UPSIT was the only variable that significantly predicted the diagnosis of EOAD versus eoMCI (odds 8 ratio 1.25; 95% CI 1.006, 1.558; p= 0.04), over the cognitive measures (table 2A) . Whereas
MMSE predicted diagnosis of eoMCI versus HC.
There were no sex differences in the UPSIT scores for the whole sample and individual groups. The UPSIT scores did not correlate with total NPI or total BADL for the EOAD group.
DISCUSSION
The study investigated OI deficits in early onset AD and MCI, an area where there is lack of data and is understudied. Albeit in a small sample, the findings of our study are interesting in that it shows impaired OI in people with EOAD compared to eoMCI and HC. Impairment in OI was significantly associated with EOAD diagnosis versus eoMCI, adjusting for age, sex, education, MMSE and CAMCOG. As previously identified in late onset AD (Velayudhan et al., 2013) , a strong relationship between olfaction and cognition was also found in EOAD subjects. There was no difference in UPSIT scores between eoMCI and HC subjects, i.e., eoMCI had no OI impairment.
The mean UPSIT scores for our EOAD cohort was higher than seen in later onset AD studies (mean from 18.1 to 20.6) (Rahayel et al., 2012; Velayudhan et al., 2015) . We found no sex differences for olfactory identification deficits which is in keeping with previous study (Djordjevic et al., 2008) . None of the patient participants reported subjective impairment in olfaction voluntarily. Interestingly, only 6% of late onset AD patients were aware of their olfactory impairment, despite being identified in 90% (Doty et al., 1987) . Also its now reported that in cognitively healthy participants, subjective loss of smell is an independent predictor of dementia onset (Stanciu et al., 2014) and mortality (Ekstrom et al., 2017) , but in 9 cognitively compromised patients, smell deficits go unnoticed.
UPSIT scores in eoMCI group in our study did not differ from HC contrary to the reports from previous studies albeit in older adults (Roalf et al., 2017) . Without validation of these results, a link between olfaction and eoMCI cannot be ruled out, although presence of a different disease-causing process to that of elderly MCI could be considered. It is also interesting to note that eoMCI patients in our study had higher prevalence of TIA, MI and diabetes which are known risk factors for vascular cognitive impairment (table 1) , and possibly our study eoMCI participants are not necessarily pre-AD or developing AD pathology.
We found OI was associated with attention, executive function and praxis within EOAD group. Previous research has found a relationship between olfaction and attention/executive functioning in healthy older adults, MCI, and AD (Djordjevic et al., 2008; Lehrner et al., 2009; Makizako et al., 2014) . Impairment in odour identification in mid-life (35-64 years) has been associated with slightly poorer performance on cognitive function tests of attention, processing speed and executive function (Schubert et al., 2013) .
Clinically, challenges are seen in AD diagnosis despite comprehensive guidelines (McKhann et al., 2011; WHO, 2015) . This is particularly in younger patients where AD is uncommon and less likely to be considered as part of a differential diagnosis, especially in the absence of a suggestive family history. Subsequently, for many patients this can lead to a lengthy, drawn out period between initial symptoms of dementia and ultimate specialist referral and 10 diagnosis. Although current biomarkers are invaluable in AD diagnosis, many are expensive and particularly invasive procedures rendering them difficult for extensive use in screening for dementia. The need to aid diagnosis ideally through cheap, non-invasive, reliable tools is apparent. OI testing has been suggested as a potential tool for increasing diagnostic accuracy in AD as a clinical biomarker adjunct (Wesson et al., 2010) .
The main limitation of the study is the small sample size. The limitations of this study include the cross-sectional design which prohibits determining causality or direction of the associations seen. A further limitation, which could be overcome in future research, is to make additional comparisons with different groups, such as adults of a similar age with cognitive impairment with other neurodegenerative disorders. The strengths of this study include the well-defined participants and the use of standardized measures of odor identification and cognitive function that were administered by trained researchers. In addition, detailed demographic, health and behavioral data were available.
In conclusion, albeit in a small sample, our study found impaired OI in people with EOAD compared to eoMCI and HC and also that OI impairment was significantly associated with a diagnosis of EOAD (versus eoMCI) while cognitive tests were not. OI in EOAD was associated with poorer performance in attention, executive functions and praxis. Further work, with larger cohorts, including people with different causes of cognitive impairment and in longitudinal studies is needed. This will give greater insight into the potential of OI testing used in combination with other diagnostic tests, for improving early detection of EOAD in clinical settings. 
